Live tape
Top 8, mentions 7d14,361NVDA4,866 mentions▲ +0.04GOOGL2,064 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,110 mentions▲ +0.05TSLA955 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

INBX

NASDAQ

Inhibrx Biosciences (INBX)

87 USD −2.25% vs prior close
Inhibrx Biosciences, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
1.3B USD
Revenue, year to Dec 2025
1.3M USD
EPS, diluted, year to Dec 2025
−9.04 USD
52-week range
21 USD – 142 USD
Avg volume
83.9K

as of Jul 17, 2026

Have Inhibrx Biosciences (INBX) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Inhibrx Biosciences insiders reported 5 open-market sales and 8 purchases (SEC Form 4).

Form 4, 90 days to 10 Nov 2026, newest reported trade 14 Oct 2026

8buys
5sells
$6.07Mnet bought
0other filings
Have Inhibrx Biosciences (INBX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
14 Oct 2026Lappe MarkChief Executive OfficerBuy10,040849K USD
28 Sep 2026Lappe MarkChief Executive OfficerBuy4,500453K USD
25 Sep 2026Lappe MarkChief Executive OfficerBuy5,500545K USD
23 Sep 2026Kayyem Jon FaizDirectorBuy5,000500K USD
16 Sep 2026Kayyem Jon FaizDirectorBuy5,000500K USD
15 Sep 2026MANHARD KIMBERLYDirectorSell50053K USD
14 Sep 2026MANHARD KIMBERLYDirectorSell50055K USD
11 Sep 2026MANHARD KIMBERLYDirectorSell50056K USD
09 Sep 2026MANHARD KIMBERLYDirectorSell50058K USD
08 Sep 2026FORSYTH DOUGLASDirectorBuy2,500287K USD
08 Sep 2026Lappe MarkChief Executive OfficerBuy25,0002.6M USD
08 Sep 2026Kayyem Jon FaizDirectorBuy5,000568K USD
Bought8 open-market purchases62,540$6.35M
Sold5 open-market sales2,500$279K

Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.

Which funds hold Inhibrx Biosciences (INBX)?

8 of the 45 institutional funds we track reported a Inhibrx Biosciences position for the quarter ended 30 Jun 2026 — a combined 133.3M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Inhibrx Biosciences (INBX)?
FundPositionSharesValueShares q/q
Viking Global InvestorsHeld (±25%)1,123,929106.5M USD−21.8%
Millennium ManagementTrimmed147,20013.9M USD−55.1%
Renaissance TechnologiesHeld (±25%)62,2015.9M USD+23.9%
Point72 Asset ManagementNew position26,0112.5M USD
D. E. Shaw & Co.Trimmed22,3222.1M USD−71.2%
AQR Capital ManagementAdded11,2471.1M USD+34.2%
Marshall WaceTrimmed8,800834K USD−57.9%
Balyasny Asset ManagementNew position4,728448K USD
Citadel AdvisorsExited
Tudor Investment CorpExited

What has been filed or recorded for Inhibrx Biosciences (INBX)?

The filings we hold for Inhibrx Biosciences, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Inhibrx Biosciences (INBX)?
And
09 Oct 2026Fails to deliverShares failed to deliver383 shares36K USD notional · 0.003% of shares out
08 Oct 2026Fails to deliverShares failed to deliver18 shares2K USD notional · <0.001% of shares out
06 Oct 2026Fails to deliverShares failed to deliver88 shares8K USD notional · 0.001% of shares out
05 Oct 2026Fails to deliverShares failed to deliver88 shares9K USD notional · 0.001% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −2.34 USD
30 Jun 2026FinancialsTotal assets154.2M USDat period end
30 Jun 2026FinancialsTotal equity−53.0M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −2.15 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −9.04 USDRevenue $1M
31 Dec 2025FinancialsRevenue1.3M USDfiscal year
31 Dec 2025FinancialsNet income−140.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−9.04 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −2.28 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −1.85 USDRevenue $1M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −2.80 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 112.62 USDRevenue $0M
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −2.84 USD

What do people ask about Inhibrx Biosciences (INBX)?

From live data
What is Inhibrx Biosciences’ market cap?1.3B

Inhibrx Biosciences is worth 1.3B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Inhibrx Biosciences’ revenue?1.3M

Inhibrx Biosciences reported revenue of 1.3M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Inhibrx Biosciences insiders bought or sold shares recently?5 sales

In the 90 days to 10 Nov 2026, Inhibrx Biosciences insiders reported 5 open-market sales and 8 purchases (SEC Form 4). See Insiders

Which funds own Inhibrx Biosciences?8 of 45

8 of the 45 funds we track reported a Inhibrx Biosciences position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, Millennium Management and Renaissance Technologies. See Funds

When did Inhibrx Biosciences last report earnings?−2.34

Inhibrx Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −2.34 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings